XNASINZY
Market cap97mUSD
Jan 14, Last price
1.51USD
1D
-12.21%
1Q
-71.56%
IPO
-91.79%
Name
Inozyme Pharma Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
27.92%
Rev. gr., 5y
%
Revenues
0k
Net income
-71m
L+8.74%
CFO
-71m
L+22.36%
Earnings
Mar 10, 2025
Profile
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 76,939 | 69,852 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (76,939) | (69,852) | ||||
NOPBT Margin | ||||||
Operating Taxes | (1,614) | |||||
Tax Rate | ||||||
NOPAT | (76,939) | (68,238) | ||||
Net income | (71,169) 8.74% | (65,447) 16.01% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 85,647 | 68,830 | ||||
BB yield | -38.78% | -173.59% | ||||
| Debt | ||||||
Debt current | 1,820 | 816 | ||||
Long-term debt | 47,505 | 8,601 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 124 | |||||
Net debt | (139,264) | (118,803) | ||||
| Cash flow | ||||||
Cash from operating activities | (70,675) | (57,761) | ||||
CAPEX | (298) | (410) | ||||
Cash from investing activities | (53,646) | (5,403) | ||||
Cash from financing activities | 125,969 | 72,788 | ||||
FCF | (75,893) | (67,440) | ||||
| Balance | ||||||
Cash | 188,589 | 127,866 | ||||
Long term investments | 354 | |||||
Excess cash | 188,589 | 128,220 | ||||
Stockholders' equity | (285,883) | (214,962) | ||||
Invested Capital | 473,864 | 340,459 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 51,839 | 37,763 | ||||
Price | 4.26 305.71% | 1.05 -84.60% | ||||
Market cap | 220,835 456.94% | 39,651 -75.32% | ||||
EV | 81,571 | (79,152) | ||||
EBITDA | (76,106) | (69,108) | ||||
EV/EBITDA | 1.15 | |||||
Interest | 3,333 | 1,614 | ||||
Interest/NOPBT | ||||||